# Why invest in Redcare.

Our Investment Case



# About us ...






"Over 20 years ago in a local pharmacy in Cologne, Germany, a young pharmacist had the idea to digitise the family business. Shop Apotheke was born. Fast forward to today, and Redcare is *Europe's leading online pharmacy*."



Innovation is in our DNA.



# From humble beginnings to becoming healthcare experts.



Opening of new distribution

# German roots, <u>European footprint</u>.

With well-known brands across 7 countries:

























# We are building the <u>one-stop</u> <u>pharmacy</u> of the future.



At our core, we are a pharmacy, combining OTC, BPC and Rx offerings.

We operate a pure B2C model and are customer centric.



Our customer-centric solutions are realised through a scalable platform model that is driven by digital innovation.



Our goal is to be the market leader in all our countries.



# Our <u>one-stop</u> <u>pharmacy</u>.



MARKETPLACE

Greater assortment in Germany, Austria, Belgium and Italy.





**MEDICATION MANAGEMENT** 

MyTherapy by smartpatient



**OWN BRANDS** 

BEAVITA • nu3 • SKINTIST • Redcare



**SAME-DAY DELIVERY** 

- Now! in Germany, Austria and Belgium
- As well as classic delivery (1-2 days)



- Putting the pharmacy in the customer's pocket
- Now also offering CardLink in Germany for Rx



# The <u>leading online brand</u>.



**APPAREL** 

**ELECTRONICS** 

PHARMA

zalando





**OFFLINE** 





No significant offline brand in Continental Europe



# Redcare Pharmacy FY 2024.



12.5 M Active customers



36.5 M

**Orders** 



€ 2.4 bn

Revenue



510 M

Site visits



88%

Repeat orders (avg.)



23%

Gross margin



69

**Net Promoter Score (NPS)** 



€ 60.98

Avg. shopping basket value



1.4%

Adj. EBITDA margin



# Redcare Pharmacy Q1 2025.



13.1 M Active customers



11.5 M

**Orders** 



€ 717 M Revenue



152 M

Site visits



89%

Repeat orders



23.3%

Gross margin



64

**Net Promoter Score (NPS)** 



€ 62.44

Avg. shopping basket value



1.3%

Adj. EBITDA margin




# Our investment case.






# A <u>large</u> and <u>attractive</u> market.



- Significantly large pharmaceutical retail market.
- Largely untapped by online pharmacies; potential for increased penetration.
- Highly fragmented, requiring local knowledge and expertise.
- Undifferentiated products highly suitable for online retail, where convenience and price matter.
- Aging population.
- Increased prevalence of chronic illnesses.
- Attractive unit economics.





# Germany: the <u>largest market</u> in Europe.

<u>Attractive</u> and <u>large market</u> with total revenue of over € 66 billion in 2023, of which € 61 billion from drug sales.

#### <u>Prescription drug market size of € 55,7 billion.</u>


- Germany is a mature online market, exhibiting a high online share of OTC sales (21-25%, 2023), especially:
  - for chronic diseases;
  - high priced medication;
  - sensitive or confidential category medication.
- Rx online sales still ~ 1%.
- Rx attractive unit economics: high value, lightweight package; low return rate.




- Some 7.6 million aged 65 or older take
   5 or more prescribed medicines per day.
- One in three between the ages of 75 – 80 take more than 8 prescribed medications.

Rx online *Allowed* 

OTC online <u>Allowed</u>





85 million

Sources: ABDA, EAEP, Statista, Eurostat




# Germany:

# once-in-a-lifetime <u>opportunity</u>.


(1)

Redcare Pharmacy has a leading position.

- Online Rx sales have been allowed since 2004.
- The e-prescription became mandatory in 2024, finally opening up full access to this large market.
- There is a ban on third-party ownership of pharmacies and the regulatory landscape is complex.
- As an example, in Sweden, online penetration is now at 13.4% (Rx).




- Germany is our oldest, largest market.
- We have a strong, established and trusted brand.
- We are a pharmacy, not just an online shop.
- We offer a large assortment of Rx, OTC & BPC, at attractive prices (OTC & BPC).
- We are e-pharmacy experts who mine data and continuously improve our customer-centric solutions.
- Our modern logistics centre in the Netherlands has a large capacity and is ideally located.








# Opportunities in other markets.














Sources: ABDA, EAEP, Eurostat



## Holding the key

## to Europe's pharmacy market.



#### Growth.

More to come from:

- Demographic changes in Europe.
- More chronic conditions among all age groups.
- Health awareness, higher health expenditure.
- Policy changes (enabling mail-order Rx)
- Increased digitisation.

2 5

#### Expertise.

Over 20 years' experience and a scalable platform model offering:


- Complementary services and benefits.
- Customised experience for various use-cases.
- Access and convenience 24/7.



#### Profitability.

Mid- to long-term, adj. EBITDA of >8%

- > Scale (International).
- Operational and overhead efficiencies.
- Media income.
- Marketplace.
- Electronic script in Germany.



Our online journey is just getting started.



#### **₹** Redcare



# We are AAA

(MSCI ESG rating)

# and "low risk"



(Morningstar Sustainalytics)






# Financial & KPI Appendix.

### Historical:


## revenues and earnings.



#### Revenue (in millions of euro)



#### Gross profit margin (in millions of euro)





# Summary FY 2024: revenues and earnings.



C A	EC
<b>5</b> A	

#### DACH

Rx

€ 749.8 M

Non-Rx € 1,184.3 M

#### **INTERNATIONAL**

Non-Rx € 436.5 M GROUP

€ 2,370.6 M

GROSS PROFIT (margin)

€ 437.8 M

€ 108 M

€ **545**.8 M 23%

EBITDA ADJ. EBITDA ADJ. EBITDA MARGIN € 47.4 M € 49.9 M 2.6% € -18.2 M

€ -16.6

-3.8%


€ **29**.2 M


€ 33.3 M


1.4%



# Growth across <u>all regions:</u> total sales up 28%, strong Rx momentum in Germany continues.









# <u>Sales up</u> 28% year over year, with positive EBITDA. Quarter-over-quarter improvement on <u>all levels.</u>

	Quarter over quarter		Year over year			
in millions of euro, adjusted numbers	Q4 2024	Q1 2025	Better or (worse)	Q1 2024	Q1 2025	Better or (worse)
Sales	675	717	6.2%	560	717	28.0%
Gross profit margin	22.3%	23.3%	1.0 pp	23.4%	23.3%	(0.1) pp
Selling & distribution margin	(20.2)%	(19.4)%	0.8 pp	(18.4)%	(19.4)%	(1.0) pp
Administrative cost margin	(2.8)%	(2.7)%	0.1 pp	(2.9)%	(2.7)%	0.2 pp
Adj. EBITDA margin	(0.7)%	1.3%	2.0 pp	2.1%	1.3%	(0.8) pp
Adj. EBITDA	(5)	9	14	12	9	(3)
EBITDA	(6)	8	14	11	8	(3)



# Guidance FY 2025.

**Total sales growth** 

In excess of 25 %

**Rx Germany** 

In excess of €0.5 bn



**Total Group non-Rx sales growth** 

In excess of 18 %

Adj. EBITDA margin

2 % to 2.5 %




## Key Performance Indicators: non-financial.

	2022	2023	2024
Page visits	347,765,913	439,676,007	509,913,725
Mobile page visits	251,718,600	330,088,835	389,947,483
Ratio mobile	72 %	75 %	76 %
Orders	24,043,157	29,413,020	36,505,710
Repeat orders	83 %	85 %	88 %
Return rate	0.73 %	0.78 %	0.74 %
Active customers	9,311,375	10,848,777	12,536,581
Average shopping basket	€ 58,28	€ 59,40	€ 60,98



## Key Performance Indicators: non-financial.

	Q1 2024	Q1 2025
Page visits	126,714,104	151,849,020
Mobile page visits	98,088,607	116,217,153
Ratio mobile	77 %	77 %
Orders	8,876,659	11,522,445
Repeat orders	87 %	89 %
Return rate	0.76 %	0.66 %
Active customers	11,193,217	13,146,634
Average shopping basket	€ 58,92	€ 62,44





# Thank You!





**Investor Relations** 

investors@redcare-pharmacy.com

